🇺🇸 FDA
Pipeline program

Odronextamab

R1979-ONC-22102

Phase 3 small_molecule active

Quick answer

Odronextamab for Relapsed/Refractory Follicular Lymphoma is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Relapsed/Refractory Follicular Lymphoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials